Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas.
作者： I Thirkettle , P Harvey , P S Hasleton , R Y Ball , R M Warn
DOI: 10.1046/J.1365-2559.2000.00888.X
关键词:
摘要: Aims To assess the immunoreactivity of malignant mesotheliomas for N- and E-cadherins, hepatocyte growth factor/scatter factor (HGF/SF) tyrosine kinase receptors, met erbB-2. Methods results Pleural were stained using a standard indirect immunoperoxidase method applied to paraffin sections. Malignant immunoreactive N-cadherin (26/29; 90%), (29/29; 100%) erbB-2 (28/29; 97%). Focal was present E-cadherin in epithelioid or mixed tumours (14/25; 56%), HGF/SF (9/24; 38%). Conclusions Expression supports diagnosis mesothelioma use appropriate antibodies would be useful addition diagnostic antibody panel. staining does not exclude mesothelioma. Signalling pathways mediated via may play role spread mesotheliomas.
sci-hub.st 参考文章(18)
W. D. Travis, T. V. Colby, B. Corrin, Y. Shimosato, E. Brambilla, Histological Classification of Lung and Pleural Tumours Springer, Berlin, Heidelberg. pp. 21- 24 ,(1999) , 10.1007/978-3-642-60049-4_2
Livio Trusolino, Luisa Pugliese, Paolo M. Comoglio, Interactions between scatter factors and their receptors: hints for therapeutic applications The FASEB Journal. ,vol. 12, pp. 1267- 1280 ,(1998) , 10.1096/FASEBJ.12.13.1267
Aaron C Han, Alejandro Peralta-Soler, Karen A Knudsen, Margaret J Wheelock, Keith R Johnson, Hernando Salazar, Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues Human Pathology. ,vol. 28, pp. 641- 645 ,(1997) , 10.1016/S0046-8177(97)90171-4
Leers, Aarts, Theunissen, E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma Histopathology. ,vol. 32, pp. 209- 216 ,(1998) , 10.1046/J.1365-2559.1998.00349.X
J. Peto, F.E. Matthews, J.T. Hodgson, J.R. Jones, Continuing increase in mesothelioma mortality in Britain The Lancet. ,vol. 345, pp. 535- 539 ,(1995) , 10.1016/S0140-6736(95)90462-X
V. ASCOLI, C. CARNOVALE. SCALZO, F. NARDI, C‐ErbB‐2 Oncoprotein Immunostaining In Serous Effusions Cytopathology. ,vol. 4, pp. 207- 218 ,(1993) , 10.1111/J.1365-2303.1993.TB00090.X
Massimo Pignatelli, INTEGRINS, CADHERINS, AND CATENINS : MOLECULAR CROSS-TALK IN CANCER CELLS The Journal of Pathology. ,vol. 186, pp. 1- 2 ,(1998) , 10.1002/(SICI)1096-9896(199809)186:1<1::AID-PATH135>3.0.CO;2-T
Khalil Sheibani, Increasing role of immunopathology in diagnosis of malignant mesothelioma. Human Pathology. ,vol. 28, pp. 639- 640 ,(1997) , 10.1016/S0046-8177(97)90170-2
H. BIELEFELDT-OHMANN, A. G. JARNICKI, D. R. FITZPATRICK, Molecular pathobiology and immunology of malignant mesothelioma. The Journal of Pathology. ,vol. 178, pp. 369- 378 ,(1996) , 10.1002/(SICI)1096-9896(199604)178:4<369::AID-PATH460>3.0.CO;2-8
J. CLOVER, J. OATES, C. EDWARDS, Anti-cytokeratin 5/6: a positive marker for epithelioid mesothelioma. Histopathology. ,vol. 31, pp. 140- 143 ,(1997) , 10.1046/J.1365-2559.1997.2150833.X